
Jun 5, 2026
First human trial backs AI-designed 'universal' vaccine
A groundbreaking clinical trial has demonstrated the potential of an AI-designed vaccine aimed at providing broad protection against all variants of the coronavirus SARS-CoV-2. Developed by DIOSynVax, a spinout from the University of Cambridge, this vaccine marks the first instance of an entirely AI-generated vaccine being tested in human subjects.The vaccine, named pEVAC-PS, utilizes a DNA plasmid-based, needle-free delivery system. It was engineered using extensive genetic data collected from









